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BACKGROUND: Metabolic activity assessed by 18F-fluorodeoxyglocuse-positron emission tomography (18F-FDG-PET)
reflects biological aggressiveness and prognoses in various tumors. The authors present a correlation between tumor
metabolic activity and clinical outcomes in patients with hepatocellular carcinoma (HCC). METHODS: Over a 3-year
period (2005-2008), 135 locally advanced HCC patients were treated with localized concurrent chemoradiotherapy
(CCRT; external beam radiotherapy at 45 grays for 5 weeks plus concurrent hepatic arterial infusion of 5-fluorouracil
during the first and fifth week) followed by repetitive hepatic arterial infusional chemotherapy with 5-fluorouracil and
cisplatin. Among them, the authors studied 107 who received 18F-FDG-PET before CCRT. Maximal standardized
uptake values (SUVs) of tumors were calculated. RESULTS: The median maximal tumor SUV was 6.1 (range, 2.4-
19.2). Patients with low maximal tumor SUVs (<6.1) had a higher disease control rate than those with high maximal
tumor SUVs (6.1) (86.8% vs 68.5%, respectively, P ¼ .023). Both median progression-free survival (PFS; 8.4 vs 5.2
months; P ¼ .003) and overall survival (OS; 17.9 vs 11.3 months; P ¼ .013) were significantly longer in the low maximal
tumor SUV group than in the high maximal tumor SUV group, respectively. In multivariate analysis, low maximal tu-
mor SUV and objective responses to CCRT remained significant for PFS and OS. The high maximal tumor SUV group
was more likely to have extrahepatic metastasis within 6 months than the low maximal tumor SUV group (58.1% vs
26.8%, respectively; P < .001). Similar results were obtained for the maximal tumor SUV/normal liver maximal SUV ra-
tio (<2 vs 2) concerning progression, death, and extrahepatic metastasis. CONCLUSIONS: Metabolic activity may
be useful not only in predicting prognosis and treatment responses, but also in establishing optimal treatment plans
in locally advanced HCC. Cancer 2011;117:4779–87. VC 2011 American Cancer Society.
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Hepatocellular carcinoma (HCC), which accounts for>5% of cancers globally, is ranked as the sixth most com-
mon cancer and third leading cause of cancer-related death worldwide.1 The incidence of HCC is rising in developed
countries and continues to be high in endemic areas such as Asia.1,2 Although surgical resection or local ablative therapies
such as radiofrequency ablation and percutaneous ethanol injection achieve the best outcomes, with a 5-year survival rate
of 60%-70% in patients treated during early stages, only about 30% are amenable to potentially curative treatments.3,4
For the majority of HCC patients, these treatment modalities with curative intent are no longer feasible, because of
advanced diseases, including extensive tumor burden with portal vein thrombosis and intratumoral/extratumoral spread,
or poor liver function at presentation.3,4
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To date, several therapeutic options, such as transhe-
patic arterial chemoembolization, external/internal irradi-
ation, and molecular targeted agents, have been evaluated
for advanced HCC, and sorafenib is now recommended
as a category 1 drug in such cases owing to its proven sur-
vival benefits over the best supportive care.5-7 However, a
treatment of choice has yet to be established in locally
advanced HCC without extrahepatic metastasis. Among
various treatment modalities, 3-dimensional conformal
radiation therapy (3DCRT) has made it possible to esca-
late the irradiation dose for advanced HCC without
undue dose-limiting toxicity, and is now recognized as a
potentially curative option.8 Recently, the combination of
intra-arterial chemotherapy and localized 3DCRT has
been reported to improve treatment response rates, com-
pared with the poor outcomes experienced with mono-
therapy for locally advanced solid tumors. This finding
supports a beneficial interaction between radiotherapy
and chemotherapy.8-11 So far, localized concurrent
chemoradiation therapy (CCRT) followed by repetitive
hepatic arterial infusional chemotherapy (HAIC) in
locally advanced HCC without extrahepatic metastasis
has been attempted at several institutions, with promising
results.9
Conversely, positron emission tomography (PET)
imaging using 18F-fluoro-2-deoxyglucose (18F-FDG) is
an imaging technique based on the increased rate of glu-
cose uptake in several kinds of malignant tumors.12,13 So
far, 18F-FDG-PET has been proposed as a prognostic pre-
dictor as well as a noninvasive measurement of the biolog-
ical aggressiveness of the tumor in the field of oncology.
Likewise, in HCC, several investigators have reported that
18F-FDG uptake evaluated by preoperative PET scan is
associated with tumor differentiation as well as recur-
rences and survival after resection or transplantation.14-17
Hence, it is feasible that 18F-FDG uptake on PET scan,
like size and number criterion, might be an important
prognostic factor in the establishment of treatment and
surveillance plans. However, most studies on HCC and
18F-FDG-PET have focused primarily on either tumor
detection in preoperative settings or prognostic value in
patients treated with resection or transplantations. There
are few data on the clinical significance of 18F-FDG-PET
in HCC patients who have undergone nonsurgical treat-
ments.14,15,17-19 Furthermore, to date, there have been no
data on the appropriate application of the clinical signifi-
cance of 18F-FDG-PET in patients who have undergone
localized CCRT followed by repetitive HAIC for locally
advanced HCCs.
Here, we investigated the value of metabolic activity
assessed by 18F-FDG-PET as a prognostic factor in
patients who were treated with localized CCRT followed
by HAIC for locally advanced HCCs.
MATERIALS AND METHODS
Patient Eligibility
In this study, we consecutively enrolled patients with locally
advanced HCC without extrahepatic metastasis who
received localized CCRT at Severance Hospital, Yonsei
University College of Medicine between January 2005 and
June 2008. Diagnosis of HCC was based upon pathologic
confirmation or typical appearance of HCC on 2 dynamic
imaging examinations (computed tomography [CT] and
magnetic resonance imaging [MRI]), or via 1 dynamic
technique with elevated serum a-fetoprotein (AFP; >400
ng/mL).20 18F-FDG-PET/CT scans were obtained 10 to
14 days before the initiation of localized CCRT.
Eligible patients for localized CCRTmet the follow-
ing criteria: at least 1 unidimensionally measurable lesion,
age 18 to 75 years, an Eastern Cooperative Oncology
Group performance status of 0 to 1, life expectancy of at
least 3 months, Child-Pugh class A or B, and adequate
function in other organs (serum creatinine <1.5mg/dL,
aminotransferase <5 the upper limit of normal, abso-
lute neutrophil count 1500 cells/lL, platelet count
75,000/lL, and hemoglobin 10 g/dL). Patients with
diffuse or multifocal bilobar tumors were not considered
to be eligible for localized CCRT, because whole liver irra-
diation can cause serious hepatic toxicity. Other exclusion
criteria for localized CCRT included extrahepatic or
another concurrent malignancy, experience of recent
upper gastrointestinal bleeding, and any other underlying
serious medical condition interfering with participation
in the study. Among patients who underwent localized
CCRT according the above criteria, those who underwent
18F-FDG-PET/CT before the initiation of treatment
were included in the study. The modified International
Union Against Cancer TNM staging system21 and Barce-
lona Clinic Liver Cancer staging systems22 were adopted.
The study protocol was in accordance with the ethi-
cal guidelines of the 1975 Declaration of Helsinki. Writ-
ten, informed consent was obtained from each participant
or a responsible family member.
Treatment Protocols
Under the standard localized CCRT protocol, patients
received a total radiation dose of 45 grays in 25 fractions
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over a period of 5 weeks, with concurrent hepatic arterial
infusion of 5-fluorouracil (500 mg/d for 5 hours on
5 consecutive days through an implanted port system)
during the first and fifth weeks of radiotherapy.9 This
localized CCRT was followed by repetitive HAIC with
5-fluorouracil (500 mg/m2 for 5 hours on 3 consecutive
days) and cisplatin (60 mg/m2 for 2 hours on a single
day), administered through a port system every 4 weeks
for 2 to 12 cycles, depending on the tumor responses.9
The standard localized CCRT and HAIC protocols were
strictly maintained during the study period.
PET Imaging
All patients fasted for at least 6 hours before an 18F-FDG-
PET/CT scan. Scanning was performed when the plasma
glucose level before administration of 18F-FDG was
<130 mg/dL. Scanning was initiated about 1 hour after
administration of 18F-FDG. The median time to scan-
ning after injection was 60 minutes (range, 57-61
minutes). A low-dose noncontrast CT scan was obtained
for attenuation correction using the following parameters:
120 kVp, 50 mAs, 0.5 seconds rotation time, 5.0 mm
scan reconstruction, 60 cm field of view, and a 512 512
matrix for the Gemini. Images from the neck to the proxi-
mal thighs were obtained using the Phillips Gemini PET
scanner (Phillips-ADAC Medical Systems, Hanover,
Mass) with a spatial resolution of 5.3 mm in the center of
the field of view. Data were acquired in a 3-dimensional
(3D) mode after an intravenous administration of 370 to
444 MBq of 18F-FDG. After PET imaging, contrast-
enhanced CT images were acquired (intravenously bolus
60% wt/vol at 1.5-2.0 mL/s). The obtained PET images
were reconstructed using the 3D row-action maximum
likelihood iterative reconstruction algorithm (interation
number, 2; relaxation parameter, 0.006).
PET Interpretation
Two experienced nuclear medicine specialists, who were
unaware of the clinical information, were responsible for
reading the 18F-FDG-PET/CT images. In the cases of dis-
crepancy in determining target tumor lesions, a consensus
was reached and was used for analysis. Positive malignant
FDG uptake was defined as an abnormal increase in com-
parison with the background activity in the surrounding
tissue. The standardized uptake value (SUV) was assessed
by region of interest (ROI) analysis with guidance from
the CT or MRI scans and calculated as the activity con-
centration detected in the lesion divided by the injected
activity, with correction for radioactive decay and body
weight (lCi/g). The maximal tumor SUV was the peak
SUV in 1 pixel with the highest counts within the ROI
and in the case of multiple tumors, the maximal tumor
SUV was defined as the highest value of the tumors.
For normal liver regions, 3 circular ROIs of about
100 mm3 each were drawn, 2 in the right lobe and 1 in
the left lobe, at a location where tumor was not detected
on other images and the maximal SUV of normal liver
was defined as the highest of the 3 ROIs drawn on normal
liver. Thereafter, another metabolic parameter suggested
by the previous investigator,15 maximal tumor SUV/nor-
mal liver maximal SUV ratio was calculated.
Response Evaluation
The response evaluation was carried out with a dynamic
CT scan or MRI, if appropriate, first at 1 month after
completion of localized CCRT and then after every 2
cycles of HAIC. We adopted the Response Evaluation
Criteria in Solid Tumors, as follows: complete response
(CR), partial response (PR), stable disease (SD), and pro-
gressive disease (PD).23 Objective response was defined as
CR or PR, and disease control as CR, PR, or SD.
Response was analyzed by intention-to-treat analysis.
Statistical Analysis
The major goals of this study are to investigate clinical out-
comes of localized CCRT and to evaluate the prognostic
value of metabolic activity assessed by 18F-FDG-PET.
Continuous and categorical variables were examined using
Student t test (or the Mann-Whitney U test if appropriate)
and the chi-square test, respectively. Progression-free sur-
vival (PFS) was assessed from the date of the initiation of
localized CCRT until the date of first recurrence or death.
Overall survival (OS) was calculated as the time interval
between the date of the initiation of localized CCRT and
the date of death or last follow-up. Survival time was esti-
mated by the Kaplan-Meier method and the survival differ-
ence between groups was assessed by the log-rank test. The
Cox proportional hazards model was used for a multivari-
ate analysis of survival. All variables found significant in the
univariate analysis were included in the multivariate model.
Statistical analysis was performed using SAS soft-
ware version 9.1.3 (SAS, Cary, NC), and a 2-sided P value
<.05 was considered statistically significant.
RESULTS
Patient Characteristics
Of 137 patients who underwent localized CCRT, a total
of 107 patients who underwent 18F-FDG-PET/CT
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before localized CCRTwere included in the study sample.
Patients’ baseline characteristics are presented in Table 1.
The median age was 54 years (range, 20-75 years) and
79 (73.8%) patients were male. The median body mass
index was 22.6 kg/m2 (range, 17.2-29.8 kg/m2). The
most common etiology was hepatitis B virus infection (81
patients, 75.7%), and 101 were in Child-Pugh class A.
Eighty-two (76.6%) patients had stage IVA cancer, and
72 patients (71.0%) had portal vein thrombosis. The me-
dian maximal tumor SUV was 6.1 (range, 2.4-19.2).
Comparison of Clinical Characteristics
According to Maximal Tumor SUV
We divided the patients into 2 groups according to the
median value of the maximal tumor SUV; the low maximal
tumor SUV group (53 patients, maximal tumor SUV
<6.1) versus the high maximal tumor SUV group (54
patients, maximal tumor SUV6.1). There were no signif-
icant differences in clinical variables between the 2 groups
except for the baseline AFP level, which was marginally
higher in the high maximal tumor SUV group (Table 2).
Radiologic Responses After Treatments
After localized CCRT, 0 and 31 patients had CR and PR
(objective response rate of 28.9%), whereas 52 and 24 had
SD and PD, respectively. After subsequent HAIC, 2 and
36 had CR and PR (objective response rate of 35.5%),
whereas 45 and 24 had SD and PD, respectively.
Table 3 also shows the detailed radiologic responses
to localized CCRT and to localized CCRT plus subse-
quent HAIC according to the maximal tumor SUV.






Age, y 55.1  10.9 51.6  10.6 .101
Male sex (%) 45 (84.9) 44 (81.5) .636
ECOG, 0:1 31:22 26:28 .284
Etiology, HBV:HCV: alcohol: others 36:4:7:6 45:2:4:3 .354
White blood cell count per lL 6430  2137 6313  2650 .853
Hemoglobin, g/dL 13.4  1.61 13.7  1.23 .376
Platelet count, 103/lL 186  84 219  98 .064
Prothrombin time, INR 1.049  0.150 1.069  0.102 .421
Bilirubin, mg/dL 0.97  0.61 0.80  0.43 .110
Albumin, mg/dL 4.1  0.47 4.0  0.43 .457
AST, IU/L 112  54.8 94  58.5 .452
ALT, IU/L 73.2  38.9 44.9  32.7 .052
AFP, ng/mL 7313  1787 15440  2200 .040
PIVKA-II, mAU/mL 1478  752 1243  839 .132
Portal vein thrombosis 32, 60.3% 40, 74.1% .131
TNM stage, III:IVA 13:40 12:42 .778
BCLC stage, B:C 21:32 14:40 .131
Child-Pugh class, A:B 49:4 52:2 .437
Abbreviations: AFP, a-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BCLC, Barcelona Clinic
Liver Cancer; ECOG, Eastern Cooperative Oncology Group; HBV, hepatitis B virus; HCV, hepatitis C virus; INR, international
normalized ratio; PIVKA-II, prothrombin induced by vitamin K absence or antagonist; SUV, standardized uptake value.
Table 1. Baseline Characteristics of the Entire Patient Cohort
(n¼107)
Characteristic Value
Age median (range) 54 (20-75)
Sex, male:female 79:28
Body mass index, median kg/m2 (range) 22.6 (17.2-29.8)
Etiology
Hepatitis B/hepatitis C/alcohol/others 81/6/11/9
Biochemical values, median (range)
White cell count per lL 6000 (2600-15,500)
Hemoglobin, g/dL 13.7 (10.0-17.2)
Platelet count, 103/lL 186 (87-526)
Prothrombin time, INR 1.05 (0.7-1.7)
Total bilirubin, mg/dL 0.7 (0.2-3.0)
Albumin, g/dL 4.1 (2.5-4.9)
AST, IU/L 58 (22-145)
ALT, IU/L 42 (6-205)
AFP, ng/mL 485 (1.02-60,500)
PIVKA-II, mAU/mL (range) 2000 (10-2000)
Tumor size, median cm (range) 10.0 (3.0-21)
Tumor number, median (range) 2 (1-5)
Presence of portal vein thrombosis [main/branch] 72 [33/39]
Tumor stage III/IVA 25/82
BCLC stage B/C 35/72
Child-Pugh classification A/B 101/6
Abbreviations: AFP, a-fetoprotein; AST, aspartate aminotransferase; ALT,
alanine aminotransferase; AU, arbitrary unit; BCLC, Barcelona Clinic Liver
Cancer; INR, international normalized ratio; PIVKA-II, prothrombin induced
by vitamin K absence or antagonist.
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Patients with the low maximal tumor SUV were more
likely to have the higher disease control rate (86.8%) in
response to treatments than those with high maximal
tumor SUV (68.5%, P¼ .023).
Univariate and Multivariate Analysis for
Prognostic Factors Affecting PFS and OS
The median PFS was 6.5 months (95% confidence
interval [CI], 4.6-8.4 months). A univariate analysis
revealed that a longer median PFS was observed in
the low maximal tumor SUV group (8.4 months;
95% CI, 6.0-10.7 months) compared with the high
maximal tumor SUV group (5.2 months; 95% CI,
4.0-6.5 months; P ¼ .003) (Fig. 1). Furthermore, a
longer PFS was also observed in patients with the
lower baseline AFP level (8.4 months; 95% CI, 4.9-
11.9 months; P ¼ .030) and those with objective
responses to localized CCRT (12.0 months; 95% CI,
7.1-16.9 months; P < .001), compared with those
with the higher baseline AFP level (5.1 months; 95%
CI, 3.9-6.4 months) and those without objective
response to localized CCRT (4.9 months; 95% CI,
4.0-5.8 months), respectively. In a multivariate analy-
sis, the low maximal tumor SUV (adjusted hazard
ratio [HR], 0.481; 95% CI, 0.304-0.761; P ¼ .002)
also remained a significant independent predictor of a
lesser risk of progression, along with the objective
responses to localized CCRT (adjusted HR, 0.375;
95% CI, 0.223-0.631; P < .001) (Table 4).
The median OS was 12.6 months (95% CI, 11.3-
13.9 months). Patients with a low maximal tumor SUV
(17.9 months; 95% CI, 11.0-24.7 months) had a signifi-
cantly longer median OS than those with a high maximal
tumor SUV (11.3 months; 95% CI, 9.7-12.9 months;
P¼ .013) (Fig. 2). In addition, a longer OS was observed
in patients without portal vein thrombosis (23.1 months
[95% CI, 7.2-39.0 months] vs 11.7 months [95% CI,
10.0-13.5 months]; P ¼ .021), and in those with an
objective response to localized CCRT (27.0 months [95%
CI, 12.0-43.0 months] vs 10.9 months [95% CI, 7.8-
14.0 months]; P < .001). In a subsequent multivariate
analysis, the lowmaximal tumor SUV also remained a sig-
nificant independent predictor of a lower risk of death
(adjusted HR, 0.545; 95% CI, 0.313-0.947; P ¼ .031),
along with objective responses to treatments (adjusted
HR, 0.317; 95%CI, 0.167-0.599; P< .001).








Complete response 0 (0.0) 0 0
Partial response 31 (28.9) 16 15
Stable disease 52 (48.7) 30 22
Progressive disease 24 (22.4) 7 17
After localized CCRT plus HAIC
Complete response 2 (1.9) 1 1
Partial response 36 (33.6) 19 17
Stable disease 45 (42.1) 26 19
Progressive disease 24 (22.4) 7 17
Abbreviations: CCRT, concurrent chemoradiation therapy; HAIC, hepatic arterial infusional chemotherapy; SUV, standar-
dized uptake value.
Figure 1. Kaplan-Meier analysis of progression-free survival
according to maximal tumor standardized uptake value
(tumorSUVmax) is shown.
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Maximal Tumor SUV and Extrahepatic
Metastasis
Patients with a high maximal tumor SUV had a significantly
higher incidence of extrahepatic metastasis (14 patients,
25.9%) after completion of localized CCRT than those with
a low maximal tumor SUV (4 patients, 7.5%; P ¼ .018),
with an odds ratio of 4.287 (95% CI, 1.308-14.052). In
addition, the high maximal tumor SUV group was more
likely to have extrahepatic metastasis within 6 months of the
initiation of treatment (58.1%) than the lowmaximal tumor
SUV group (26.8%, P < .001), with a HR of 2.544 (95%
CI, 1.561-4.145) (Fig. 3). A shorter median extrahepatic
metastasis-free survival was observed in the high maximal
tumor SUV group (5.7 months; 95% CI, 4.9-6.6 months)
compared with the low maximal tumor SUV group (13.8
months; 95%CI, 9.8-17.7months; P< .001) (Fig. 3).
Another Metabolic Parameter, Maximal Tumor
SUV/Normal Liver Maximal SUV Ratio
We tested another metabolic parameter suggested by the
previous investigator,15 that is, maximal tumor SUV/
Figure 2. Kaplan-Meier analysis of overall survival according
to maximal tumor standardized uptake value (tumorSUVmax)
is shown.
Figure 3. Kaplan-Meier analysis of extrahepatic metastasis-
free survival according to maximal tumor standardized
uptake value (tumorSUVmax) is shown.












Age, <55 vs  55 years .973 — .381 —
Sex, male vs female .466 — .731 —
ECOG, 0 vs 1 .309 — .014 —
Etiology, HBV vs HCV vs others .329 — .549 —
Child-Pugh class, A vs B .698 — .193 —
Portal vein thrombosis, yes vs no .075 — .021 NS
AFP, <200 ng/mL vs 200 ng/mL .030 NS .323 NS
PIVKA-II, <600 mAU/mL vs 600 mAU/mL .714 — .641 —
TNM stage, III vs IVA .875 — .961 —
Maximal tumor SUV, <6.1 vs 6.1 .003 .002 .013 .031
Objective responses after localized CCRT <.001 <.001 <.001 <.001
Abbreviations: AFP, a-fetoprotein; CCRT, concurrent chemoradiation therapy; ECOG, Eastern Cooperative Oncology
Group; HBV, hepatitis B virus; HCV, hepatitis C virus; NS, not significant; PIVKA-II, prothrombin induced by vitamin K
absence or antagonist; SUV, standardized uptake value.
a Expressed as P value.
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normal liver maximal SUV ratio, which showed consist-
ent results with maximal tumor SUV in this study. There
was a significant correlation between the maximal tumor
SUV and maximal tumor SUV/normal liver maximal
SUV ratio by Pearson correlation test (r ¼ 0.799, P <
.001). By using the suggested cutoff value of 2.0, we
observed significantly longer median PFS in those with
maximal tumor SUV/normal liver maximal SUV ratio
<2.0 (9.4 months [95%CI, 3.5-15.3 months]) compared
with those with maximal tumor SUV/normal liver maxi-
mal SUV ratio 2.0 (5.4 months [95% CI, 4.3-6.4
months]), with a lesser risk of progression (HR, 0.603;
95% CI, 0.390-0.931; P ¼ .022). Likewise, longer me-
dian OS in those with maximal tumor SUV/normal liver
maximal SUV ratio <2.0 (17.9 months [95% CI, 6.7-
29.0 months]) was observed compared with those with
maximal tumor SUV/normal liver maximal SUV ratio
2.0 (11.7 months [95% CI, 10.0-13.5 months]), with a
lesser risk of death (HR, 0.586; 95% CI, 0.354-0.970; P
¼ .038). In addition, those with maximal tumor SUV/
normal liver maximal SUV ratio2.0 were more likely to
have extrahepatic metastasis within 6 months of the initia-
tion of treatment (50.9%) than those with maximal tumor
SUV/normal liver maximal SUV ratio <2.0 (28.7%),
with an HR of 2.269 (95%CI, 1.382-3.726; P< .001).
DISCUSSION
Malignant tumors including HCC are known to have
increased glycolysis compared with normal tissues.24 The
increased activities of enzymes involved in glucose uptake
and intracellular glycolytic metabolism, such as glucose
transporter protein, hexokinase, and phosphofructoki-
nase, result in the increased uptake of 18F-FDG in tumor
cells.24,25 However, because the expression of glucose-6-
phosphatase enabling 18F-FDG to accumulate in tumor
cells varies widely in HCC, only 50% to 70% of HCC
cases have positive 18F-FDG uptake, in contrast to meta-
static liver cancer or cholangiocarcinoma.26,27 Thus, we
undertook the current study with the assumption that
such metabolic diversity in HCC may lead to differences
in biological characteristics, treatment outcomes, and ulti-
mately prognosis. So far, most previous studies of HCC
and 18F-FDG-PET have primarily focused on either
detection of extrahepatic metastasis in preoperative set-
tings or prognostic significance in patients who were
treated with surgical resection or transplantation.14,15 To
our knowledge, this is the first study to evaluate the prog-
nostic value of quantitative metabolic activity and its cor-
relation with clinical outcomes in subjects who have
undergone localized external beam radiotherapy along
with concurrent intra-arterial chemotherapy infusion per-
formed in homogeneous protocols. Considering the rela-
tively low sensitivity of 18F-FDG uptake in individual
HCCs, we selected the ROI of HCC with guidance from
dynamic CT or MRI for accurate measurement of the
maximal SUV.28 Because the combination of external
beam radiotherapy and intra-arterial chemotherapy infu-
sion has been widely applied at many institutes, the results
from our study could help physicians accurately deter-
mine disease courses and establish further treatment plans.
In the present study, the localized CCRT showed
considerable antitumor effect, with a median PFS of 6.5
months and an OS of 12.6 months, suggesting a benefit
over the best supportive care and at least comparable out-
comes with reference to sorafenib in patients with locally
advanced HCC, although this is not a direct comparative
study.5,7 As a prognostic factor, those with a low maximal
tumor SUV had a higher disease control rate, as well as
longer PFS andOS. Onmultivariate analysis, maximal tu-
mor SUV independently affected both PFS and OS along
with the objective response to CCRT. In addition, a
higher baseline AFP level was significantly associated with
worse outcome in univariate analysis of PFS, but not in
multivariate analysis. This may be primarily because of
the higher baseline AFP levels observed in patients with
high maximal tumor SUVs, suggesting that patients with
high maximal tumor SUVs may have the more aggressive
tumor biology and disease burdens.27 Regarding OS, the
presence of portal vein thrombosis was a significant factor
in univariate analysis, but not in multivariate analysis.
However, we note that most of our patients had portal
vein thrombosis, and even those without it already had
highly advanced disease, in terms of number and size.
Another metabolic parameter, maximal tumor SUV/nor-
mal liver maximal SUV ratio, showed consistent prognos-
tic implications with maximal tumor SUV in this study.
Therefore, the metabolic activity assessed by 18F-FDG-
PET might be useful in identifying subgroups with differ-
ential prognosis before treatment, considering that con-
ventional staging systems such as TNM and Barcelona
Clinic Liver Cancer stage cannot discriminate the detailed
high-risk groups in patients with locally advanced HCC
without extrahepatic metastasis, because most of them fall
into the category of TNM IVA and Barcelona Clinic Liver
Cancer C stage.
Several factors may explain the prognostic implica-
tions of maximal tumor SUV. First, increased glucose
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metabolism and resulting relative glucose depletion in in-
tracellular milieu in HCC cells might induce the expres-
sion of the multidrug resistance (MDR) gene, comprising
the treatment outcomes by activating an efflux pump to
chemotherapeutic agents.29 Second, the increased uptake
of 18F-FDG reflects the rapid growth of the HCC and
poor histologic differentiation associated with aggressive
biological behavior.17,19,26,30 In addition, the higher
expression of metalloproteinase-9 in tumor cells with
enhanced glucose metabolism might make invasion into
surrounding tissues and extrahepatic spread much eas-
ier.31 In the same context, HCC with a high uptake of
18F-FDG exhibited microvascular invasion more fre-
quently, which proved to be an important histopathologi-
cal parameter, resulting in treatment failures like
intrahepatic/extrahepatic dissemination.32,33 Thus, it is of
note that patients with the higher baseline maximal tumor
SUV were more likely to have extrahepatic metastasis
within 6 months of treatment initiation (more than 2-fold
increase of risk) compared with those with low maximal
tumor SUV. In particular, patients with high maximal tu-
mor SUV had an approximately 4-fold increase in the
incidence of extrahepatic metastasis after completion of
localized CCRT. For those high-risk patients, locore-
gional therapy, either localized radiotherapy or intra-arte-
rial chemotherapy infusion, might be insufficient for
prevention of systemic dissemination of the disease. Thus,
the addition of other systemic therapy should be consid-
ered at an earlier stage of treatment for such patients. The-
oretically, sublethal irradiation damage of HCC cells may
induce the compensatory activation of multiple intracellu-
lar signaling pathway mediators such as PI3K, MAPK,
JNK, NF-jB, and VEGF, not only leading to enhanced
intratumor angiogenesis, but also ultimately facilitating
earlier dissemination of HCC. Recent studies have shown
positive results upon maintenance of molecular target
agents such as sorafenib, along with chemoradiother-
apy.34,35 Thus, such high-risk patients may benefit from
concomitant systemic therapy such as novel agents to
block multimolecular pathways.35-37
This study has several limitations. First, quantitative
assessments of changes in maximal tumor SUV from base-
line after completion of chemoradiotherapy were not per-
formed. Further studies investigating metabolic responses
as a prognostic factor are warranted. Second, histopatho-
logic examinations on tumor specimens were not
included. Future studies covering the clinical correlation
between metabolic activity and the expression of various
regulatory enzymes and genes on tumor tissues are
required to understand the tumor biology. Third,
although maximal tumor SUV had a good correlation
with the prognosis, considering that the repeatability of
the SUV measurement is not high in a single patient,
physicians should be cautious in interpreting this meta-
bolic parameter. Therefore, further investigations to de-
velop other metabolic parameters for generating the
reproducible results are warranted.
In conclusion, we have shown that tumor metabolic
activity before therapy, assessed by 18F-FDG-PET/CT, is
an independent prognostic factor in determining survival
outcomes in patients with locally advanced HCC who
have undergone localized CCRT followed by HAIC.
Thus, it could be used as an ancillary method for risk strat-
ification in the treatment of HCC. Further studies are
required to investigate whether tumor metabolic activity
is similarly significant in other nonsurgical treatment
modalities, especially newer targeted agents.
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